Skip to main content

Advertisement

SpringerLink
Log in

Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Older women are poorly represented in trials evaluating chemotherapy for breast cancer (BC). This study aimed to describe survival and associated factors among elderly women receiving chemotherapy for non-metastatic BC.

Methods

This was a population-based cohort study including women ≥ 70 years old diagnosed with invasive, non-metastatic BC from 2010 to 2017 in SEER. Among those who received chemotherapy, overall survival (OS) was determined using Kaplan–Meier curves and hazard ratios were reported with 95% confidence intervals (CIs). Adjustment was made for available confounders. Co-morbidity is not available in SEER. BC-specific survival (BCSS) and subdistribution hazard ratios were determined using competing risks analysis.

Results

The cohort consisted of 109,239 women aged 70+, of whom 17,961 (16%) received chemotherapy. Chemotherapy patients were younger (median 73.0 years vs. 77.0), had more advanced disease (25% stage III vs. 5.2%), and were more likely to receive mastectomy (50% vs. 33%). Among chemotherapy patients, 5-year OS was 77.8% (95% CI 76.9–78.6%), and for women 80+ was 60.2% (95% CI 57.5–63.1%). More recent diagnoses, no previous history of cancer, and receipt of radiotherapy were all associated with improved BCSS. Conversely, older age, higher tumour grade, advanced stage, and human epidermal growth factors receptor (HER)2 negative tumours were associated with worse BCSS. 56% of deaths were due to BC, and women aged 80+ had worse BCSS compared to those aged 70–79 (adjusted sdHR 1.62, 95% CI 1.43–1.84).

Conclusions

Elderly women with advanced disease can achieve good survival after chemotherapy for non-metastatic BC. Those with HER2+ disease have superior survival, reinforcing benefit in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Due to the nature of this research, participants of this study did not explicitly agree for their data to be shared publicly, so supporting data are not available.

Code availability

Available upon request.

References

  1. Female breast cancer—cancer stat facts. SEER. https://seer.cancer.gov/statfacts/html/breast.html. Accessed 12 April 2019

  2. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551

    Article  PubMed  Google Scholar 

  3. Lagacé F, Ghazawi FM, Le M et al (2019) Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada. Breast Cancer Res Treat 178:683–691. https://doi.org/10.1007/s10549-019-05418-2

    Article  PubMed  Google Scholar 

  4. Goodwin JS, Hunt WC, Samet JM (1993) Determinants of cancer therapy in elderly patients. Cancer 72:594–601. https://doi.org/10.1002/1097-0142(19930715)72:2%3c594::aid-cncr2820720243%3e3.0.co;2-#

    Article  CAS  PubMed  Google Scholar 

  5. DeMichele A, Putt M, Zhang Y et al (2003) Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 97:2150–2159. https://doi.org/10.1002/cncr.11338

    Article  PubMed  Google Scholar 

  6. Mandelblatt JS, Cai L, Luta G et al (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107–117. https://doi.org/10.1007/s10549-017-4222-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Owusu C, Lash TL, Silliman RA (2007) Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 102:227–236. https://doi.org/10.1007/s10549-006-9321-x

    Article  PubMed  Google Scholar 

  8. Dotan E, Walter LC, Browner IS et al (2021) NCCN guidelines® insights: older adult oncology, version 1.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 19:1006–1019. https://doi.org/10.6004/jnccn.2021.0043

    Article  PubMed  Google Scholar 

  9. Muss HB, Polley M-YC, Berry DA et al (2019) Randomized trial of standard adjuvant chemotherapy regimens versus Capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. J Clin Oncol 37:2338–2348. https://doi.org/10.1200/JCO.19.00647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Crozier JA, Pezzi TA, Hodge C et al (2020) Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. Lancet Oncol 21:1611–1619. https://doi.org/10.1016/S1470-2045(20)30538-6

    Article  PubMed  Google Scholar 

  11. Tamirisa N, Lin H, Shen Y et al (2020) Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol 23:56–89. https://doi.org/10.1001/jamaoncol.2020.2388

    Article  Google Scholar 

  12. Janeva S, Zhang C, Kovács A et al (2020) Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. Lancet Healthy Longev 1:e117–e124. https://doi.org/10.1016/S2666-7568(20)30018-0

    Article  Google Scholar 

  13. Gajra A, McCall L, Muss HB et al (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221–227. https://doi.org/10.1016/j.jgo.2018.02.003

    Article  PubMed  PubMed Central  Google Scholar 

  14. Harder H, Ballinger R, Langridge C et al (2013) Adjuvant chemotherapy in elderly women with breast cancer: patients’ perspectives on information giving and decision making. Psychooncology 22:2729–2735. https://doi.org/10.1002/pon.3338

    Article  PubMed  Google Scholar 

  15. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? JNCI Monogr 2001:146152

    Article  Google Scholar 

  16. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH (2009) Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 27:2170–2176. https://doi.org/10.1200/JCO.2008.17.5935

    Article  PubMed  PubMed Central  Google Scholar 

  17. Aaldriks AA, van der Geest LGM, Giltay EJ et al (2013) Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol 4:218–226. https://doi.org/10.1016/j.jgo.2013.04.001

    Article  PubMed  Google Scholar 

  18. Pressoir M, Desné S, Berchery D et al (2010) Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 102:966–971. https://doi.org/10.1038/sj.bjc.6605578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Raji MA, Kuo Y-F, Freeman JL, Goodwin JS (2008) Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch Intern Med 168:2033–2040. https://doi.org/10.1001/archinte.168.18.2033

    Article  PubMed  PubMed Central  Google Scholar 

  20. Canoui-Poitrine F, Reinald N, Laurent M et al (2016) Geriatric assessment findings independently associated with clinical depression in 1092 older patients with cancer: the ELCAPA Cohort Study. Psychooncology 25:104–111. https://doi.org/10.1002/pon.3886

    Article  PubMed  Google Scholar 

  21. Wang T, Baskin AS, Dossett LA (2020) Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. https://doi.org/10.1001/jamasurg.2020.0322

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sun J, Mathias BJ, Sun W et al (2021) Is it wise to omit sentinel node biopsy in elderly patients with breast cancer? Ann Surg Oncol 28:320–329. https://doi.org/10.1245/s10434-020-08759-1

    Article  CAS  PubMed  Google Scholar 

  23. Chagpar AB, Horowitz N, Sanft T et al (2017) Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? Am J Surg 214:1082–1088. https://doi.org/10.1016/j.amjsurg.2017.07.036

    Article  PubMed  Google Scholar 

  24. Biganzoli L, Wildiers H, Oakman C et al (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148-160. https://doi.org/10.1016/S1470-2045(11)70383-7

    Article  PubMed  Google Scholar 

  25. Saleh RR, Nadler MB, Desnoyers A et al (2020) Influence of competing risks on estimates of recurrence risk and breast cancer-specific mortality in analyses of the Early Breast Cancer Trialists Collaborative Group. Sci Rep 10:4091. https://doi.org/10.1038/s41598-020-61093-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Doll KM, Rademaker A, Sosa JA (2018) Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg 153:588

    Article  Google Scholar 

  27. SEER incidence database—SEER data & software. SEER. https://seer.cancer.gov/data/index.html. Accessed 26 Feb 2019

  28. von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England) 370:1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X

    Article  Google Scholar 

  29. Summary staging manual—2018. SEER. https://seer.cancer.gov/tools/ssm/index.html. Accessed 8 Feb 2022

  30. Months survived based on complete dates. SEER. https://seer.cancer.gov/survivaltime/index.html. Accessed 29 June 2020

  31. SEER cause of death recode 1969+ (9/17/2004)—SEER data reporting tools. SEER. https://seer.cancer.gov/codrecode/1969_d09172004/index.html. Accessed 29 June 2020

  32. Lv M, Yuan P, Ma Y et al (2021) Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database. Ann Transl Med 9:1082. https://doi.org/10.21037/atm-21-3097

    Article  PubMed  PubMed Central  Google Scholar 

  33. Iqbal J, Ginsburg O, Rochon PA et al (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313:165–173. https://doi.org/10.1001/jama.2014.17322

    Article  CAS  PubMed  Google Scholar 

  34. Silber JH, Rosenbaum PR, Clark AS et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389–397. https://doi.org/10.1001/jama.2013.8272

    Article  CAS  PubMed  Google Scholar 

  35. Osei-Twum J-A, Gedleh S, Lofters A, Nnorom O (2021) Differences in breast cancer presentation at time of diagnosis for black and white women in high resource settings. J Immigr Minor Health 23:1305–1342. https://doi.org/10.1007/s10903-021-01161-3

    Article  PubMed  PubMed Central  Google Scholar 

  36. DeSantis C, Jemal A, Ward E (2010) Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes & Control: CCC 21:1445–1450. https://doi.org/10.1007/s10552-010-9572-z

    Article  PubMed  Google Scholar 

  37. Williams DR, Mohammed SA, Shields AE (2016) Understanding and effectively addressing breast cancer in African American women: unpacking the social context. Cancer 122:2138–2149. https://doi.org/10.1002/cncr.29935

    Article  PubMed  Google Scholar 

  38. Flanagin A, Frey T, Christiansen SL (2021) Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA 326:621–627. https://doi.org/10.1001/jama.2021.13304

    Article  PubMed  Google Scholar 

  39. Vyas DA, Eisenstein LG, Jones DS (2020) Hidden in plain sight—reconsidering the use of race correction in clinical algorithms. N Engl J Med 383:874–882. https://doi.org/10.1056/NEJMms2004740

    Article  PubMed  Google Scholar 

  40. Hu C-Y, Xing Y, JaniceN C, Chang GJ (2013) Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer 119:1900–1907. https://doi.org/10.1002/cncr.27968

    Article  PubMed  Google Scholar 

  41. Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:601–609. https://doi.org/10.1161/CIRCULATIONAHA.115.017719

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada

    Matthew Castelo & Adena S. Scheer

  2. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Matthew Castelo, Lawrence Paszat, Kuan Liu & Adena S. Scheer

  3. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Justin Lu

  4. Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    Lawrence Paszat

  5. Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada

    Zachary Veitch

  6. Division of General Surgery, St. Michael’s Hospital, 3-005 Donnelly Wing, 30 Bond St, Toronto, ON, M5B 1W8, Canada

    Adena S. Scheer

Authors
  1. Matthew Castelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Paszat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zachary Veitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adena S. Scheer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adena S. Scheer.

Ethics declarations

Conflict of interest

None to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 136 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castelo, M., Lu, J., Paszat, L. et al. Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis. Breast Cancer Res Treat 194, 629–641 (2022). https://doi.org/10.1007/s10549-022-06646-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06646-9

Keywords

Search

Navigation